ClinicalTrials.gg
CompletedNCT07838987Updated Oct 22, 2026

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

A Phase 1 interventional study of Embibatinib and Rabeprazole in Healthy, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2023, registered Sep 2026).
Updated Oct 22, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time. Researchers will compare what happens to different doses and forms of Embibatinib in a person's body over time when given with or without food, or with or without other medications.

The goal of the study is to learn:

  • What happens to different doses of Embibatinib in a person's body over time when it is given with or without food, or with or without other medications.
  • About the safety of Embibatinib and if people tolerate it
Read the detailed description

Per protocol, participants will be randomized in Cohort 7 to the sequence in which they receive two Embibatinib formulations. All other cohorts will be non-randomized.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

First submitted after Terns, Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has body weight ≥48 kg (105.6 lbs) and within the range of 18.5 to 32 kg/m\^2 (inclusive)
  • Is in good health

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history or clinical manifestation of any metabolic, allergic, , dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, ocular, respiratory, endocrine, or psychiatric disorder, or any condition that would affect drug absorption, distribution, metabolism, or excretion (eg, stomach or intestinal surgery, or gallbladder removal/cholecystectomy). Uncomplicated appendectomy and hernia repair will be allowed.
  • Has history of syndrome, unexplained syncope, family history of sudden death, atrial fibrillation, malignant tumor, mental disorder, or any major disease
  • Has positive screening test for surface antigen, anti- virus antibodies, or anti- (HIV) 1 and 2 antibodies
  • Has any known history of bleeding, or (Embibatinib + Probe Substrate Cocktail-2 arm only)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Cohort 1: Single Ascending Dose (SAD) Escalation of Embibatinib Dose Level 1

    Participants receive a single oral dose of Embibatinib Dose Level 1 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 2: SAD Escalation of Embibatinib Dose Level 2

    Participants receive a single oral dose of Embibatinib Dose Level 2 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 3: SAD Escalation of Embibatinib Dose Level 3 and Food Effect

    On Period 1 Day 1, participants receive a single oral dose of Embibatinib Dose Level 3 under fasted conditions. On Period 2 Day 1, participants receive Embibatinib Dose Level 3 after a high-fat meal.

    Drug: Embibatinib

  • Experimental
    Cohort 4: SAD Escalation of Embibatinib Dose Level 4

    Participants receive a single oral dose of Embibatinib Dose Level 4 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 5: SAD Escalation of Embibatinib Dose Level 5

    Participants receive a single oral dose of Embibatinib Dose Level 5 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 6: SAD Escalation of Embibatinib Dose Level 7

    Participants receive a single oral dose of Embibatinib Dose Level 7 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 7: Embibatinib Formulations with Rabeprazole 20 mg

    Participants in Cohort 7 are randomized to receive Embibatinib Formulation 1 or Formulation 2 at Dose Level 5 on Day 1. On Day 7, participants receive Embibatinib Formulation 2 or Formulation 1 at Dose Level 5. Participants also receive Rabeprazole 20 mg once daily on Days 10-13. On Day 14, participants will co-administer a single oral dose of Rabeprazole 20 mg with Embibatinib Formulation 1 Dose Level 5 at the same time. All participants receive treatment under fasted conditions.

    Drug: Embibatinib · Drug: Rabeprazole

  • Experimental
    Cohort 8: Embibatinib + Probe Substrate Cocktail-1

    Per protocol, the probe substrate cocktail-1 consists of midazolam 2 mg, digoxin 0.25 mg, pravastatin 40 mg, montelukast 10 mg, and omeprazole 40 mg. On Day 1, participants receive a single oral dose of the probe substrate cocktail-1 under fasted conditions. On Day 5, participants receive a single oral dose of Embibatinib Dose Level 4 co-administered with a single oral dose of the probe substrate cocktail-1 taken at the same time under fasted conditions. On Day 9, participants receive a single oral dose of Embibatinib Dose Level 7 co-administered with a single oral dose of the probe substrate cocktail-1 taken at the same time under fasted conditions.

    Drug: Embibatinib · Drug: Midazolam · Drug: Digoxin · Drug: Pravastatin · Drug: Montelukast · Drug: Omeprazole

  • Experimental
    Cohort 9: Embibatinib Dose Level 5 + Rabeprazole 20 mg

    Participants receive a single oral dose of Embibatinib Dose Level 5 on Day 1 under fasted conditions. On Days 4-7 participants will receive Rabeprazole 20 mg once daily under fasted conditions. On Day 8, under fasted conditions, participants co-administer a single oral dose of Embibatinib Dose Level 5 with a single oral dose of Rabeprazole 20 mg taken at the same time under fasted conditions.

    Drug: Embibatinib · Drug: Rabeprazole

  • Experimental
    Cohort 10: SAD Escalation of Embibatinib Dose Level 8

    Participants receive a single oral dose of Embibatinib Dose Level 8 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 11: SAD Escalation of Embibatinib Dose Level 9

    Participants receive a single oral dose of Embibatinib Dose Level 9 under fasted conditions on Day 1.

    Drug: Embibatinib

  • Experimental
    Cohort 12: Embibatinib Dose Level 3 + Itraconazole 200 mg

    Participants receive a single oral dose of Embibatinib at Dose Level 3 under nonfasted conditions on Day 1. On Day 8, participants will receive Itraconazole 200 mg twice daily after a standardized breakfast and evening snack. On Days 9-11, participants will take a single oral dose of Itraconazole 200 mg after a standardized meal. On Day 12, participants will take a single dose of Itraconazole 200mg after a standardized meal followed by Embibatinib Dose Level 3 taken an hour later. Participants will continue taking a single oral dose of Itraconazole 200 mg once daily after a standardized meal on Days 13-15.

    Drug: Embibatinib · Drug: Itraconazole

  • Experimental
    Cohort 13: Multiple Ascending Dose (MAD) Escalation of Embibatinib Dose Level 4

    Participants receive an oral dose of Embibatinib Dose Level 4 once daily from Day 1 to Day 13 under fasted conditions.

    Drug: Embibatinib

  • Experimental
    Cohort 14: Embibatinib Dose Level 5 + Probe Substrate Cocktail-2

    Per protocol, the probe substrate cocktail-2 consists of midazolam 2 mg, warfarin 5 mg, and rosuvastatin 10 mg. Participants receive a single oral dose of the Probe Substrate Cocktail-2 on Day 1 under fasted conditions. On Days 9-15, participants receive a single oral dose of Embibatinib Dose Level 5 once daily under fasted conditions. On Day 16, participants receive a single oral dose of the Probe Substrate Cocktail-2 co-administered with Embibatinib Dose Level 5 taken at the same time under fasted conditions. On Days 17-21 participants receive Embibatinib Dose Level 5 as a single oral dose once daily under fasted conditions.

    Drug: Embibatinib · Drug: Midazolam · Drug: Warfarin · Drug: Rosuvastatin

  • Experimental
    Cohort 15: Embibatinib Dose Level 8 + Probe Substrate Cocktail-2

    Per protocol, the probe substrate cocktail-2 consists of midazolam 2 mg, warfarin 5 mg, and rosuvastatin 10 mg. Participants receive a single oral dose of the Probe Substrate Cocktail-2 on Day 1 under fasted conditions. On Days 9-15, participants receive a single oral dose of Embibatinib Dose Level 8 once daily under fasted conditions. On Day 16, participants receive a single oral dose of the Probe Substrate Cocktail-2 co-administered with Embibatinib Dose Level 8 taken at the same time under fasted conditions. On Days 17-21 participants receive Embibatinib Dose Level 8 as a single oral dose once daily under fasted conditions.

    Drug: Embibatinib · Drug: Midazolam · Drug: Warfarin · Drug: Rosuvastatin

  • Experimental
    Cohort 16: Food Effect on Embibatinib Dose Level 8 Formulations with Rabeprazole 20 mg

    On Period 1 Day 1, participants receive a single oral dose of Embibatinib Formulation 3 Dose Level 8 (DL8). On Period 1 Day 7, participants receive a single oral dose of Embibatinib Formulation 4 DL8. On Period 1 Day 13, participants receive a single oral dose of Embibatinib Formulation 5 DL8. On Period 1 Day 19, participants receive a single oral dose of Embibatinib Formulation 6 DL8. All Period 1 treatments are administered under fasted conditions. Per protocol, following Period 1, one formulation is selected for Period 2. On Period 2 Day 1, participants receive a single oral dose of the selected Embibatinib formulation DL8 after a high-fat meal. On Period 2 Days 7-10, participants receive rabeprazole 20 mg once daily under fasted conditions. On Period 2 Day 11, participants receive the selected formulation of Embibatinib DL8 as a single oral dose, co-administered with the single oral dose of Rabeprazole 20 mg taken at the same time under fasted conditions.

    Drug: Embibatinib · Drug: Rabeprazole

  • Experimental
    Cohort 17: Food Effect on Embibatinib Dose Level 8 Selected Formulation with Rabeprazole 20 mg

    Per protocol, a formulation from Cohort 16 Period 1, different from the formulation selected for Cohort 16 Period 2, may be selected to evaluate the effects of food and rabeprazole 20 mg. On Day 1, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 under fasted conditions. On Day 7, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 after a high-fat meal. On Days 13-16, participants receive a single oral dose of rabeprazole 20 mg once daily. On Day 17, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 co-administered with a single oral dose of rabeprazole 20 mg taken at the same time under fasted conditions.

    Drug: Embibatinib · Drug: Rabeprazole

  • Experimental
    Cohort 18: Embibatinib Dose Level 8 + Bosentan 125 mg

    On Day 1, participants receive a single oral dose of Embibatinib Dose Level 8 under fasted conditions. Beginning on Day 8, participants receive an oral dose of Bosentan 125 mg twice daily. On Day 15, participants receive Embibatinib Dose Level 8 as a single oral dose co-administered with the morning dose of Bosentan 125 mg taken at the same time under fasted conditions; participants then receive the second daily dose of Bosentan 125 mg in the evening. Participants continue taking Bosentan 125 mg twice daily on Days 16-18.

    Drug: Embibatinib · Drug: Bosentan

  • Experimental
    Cohort 19: Embibatinib Dose Level 6 + Quinidine 300 mg

    Participants receive a single oral dose of Embibatinib Dose Level 6 on Day 1 under fasted conditions. Beginning on Day 6, participants receive an oral dose of Quinidine 300 mg three times daily. On Day 8, participants receive Embibatinib Dose Level 6 as a single oral dose co-administered with the morning final dose of Quinidine 300 mg taken at the same time under fasted conditions.

    Drug: Embibatinib · Drug: Quinidine

Interventions

  • Oral Tablet

    Also known as: MK-4208, HS-10382

  • DrugRabeprazole

    The United States commercially marketed 20 mg oral tablet formulation is being used in this trial.

  • DrugMidazolam

    2 mg oral syrup formulation administered as part of the probe substrate cocktail-1 and probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • DrugDigoxin

    0.25 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • 40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • 10 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • DrugOmeprazole

    40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.

  • DrugItraconazole

    The United States commercially marketed 200 mg oral capsule formulation is being used in this trial.

  • DrugWarfarin

    5 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • DrugRosuvastatin

    10 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.

  • The Europe commercially marketed 125 mg oral tablet formulation is being used in this trial.

  • DrugQuinidine

    The United States commercially marketed 300 mg oral tablet formulation is being used in this trial.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Treatment Emergent Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a treatment emergent AE will be reported.

    Time frame: Up to approximately 102 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 102 days

  3. Number of Participants with Clinically Significant Abnormalities in Systolic Blood Pressure

    Blood pressure will be measured after the participant has been at rest in a supine position for at least 10 minutes. Blood pressure and pulse measurements will be assessed with a completely automated device; manual techniques will be used only if an automated device is not available. Blood pressure measurements will be carried out before blood sample collections or at least 30 minutes after any blood draws.

    Time frame: up to approximately 102 days

  4. Number of Participants with Clinically Significant Abnormalities in Diastolic Blood Pressure

    Blood pressure will be measured after the participant has been at rest in a supine position for at least 10 minutes. Blood pressure and pulse measurements will be assessed with a completely automated device; manual techniques will be used only if an automated device is not available. Blood pressure measurements will be carried out before blood sample collections or at least 30 minutes after any blood draws.

    Time frame: up to approximately 102 days

  5. Number of Participants with Abnormal Clinical Hematology Test Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs will be reported.

    Time frame: up to approximately 102 days

  6. Number of Participants with Abnormal Clinical Chemistry Test Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs will be reported.

    Time frame: up to approximately 102 days

  7. Number of Participants with Abnormal Urinalysis Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal urinalysis-related AEs will be reported.

    Time frame: up to approximately 102 days

  8. Number of Participants with Clinically Significant Abnormalities in 12-Lead (ECG) Findings

    During the 12-lead ECG collection participants will be instructed to lie supine for at least 10 minutes prior to ECG collection. During the collection, participants should be in a quiet setting, without distractions, and should refrain from talking or moving their arms or legs. All ECG acquisitions will be carried out before any blood sample collections or at least 30 minutes after any blood draws.

    Time frame: up to approximately 102 days

  9. Area Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of Embibatinib in Plasma

    Blood samples will be collected to determine the AUC0-Last of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  10. Area Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of Embibatinib in Plasma

    Blood samples will be collected to determine the AUC0-inf of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  11. Area Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of Embibatinib in Plasma

    Blood samples will be collected to determine the AUCtau of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 24 hours post dose

  12. Maximum Observed Concentration of Drug (Cmax) of Embibatinib in Plasma

    Blood samples will be collected to determine the Cmax of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  13. Apparent Terminal Elimination Half-Life (t1/2) of Embibatinib in Plasma

    Blood samples will be collected to determine the t1/2 of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  14. Time of Maximum Observed Concentration of Drug (Tmax) of Embibatinib in Plasma

    Blood samples will be collected to determine the Tmax of Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

Secondary outcomes

  1. AUC0-last of Embibatinib in Plasma Under Fed Versus Fasted Conditions

    Blood samples will be collected to determine the AUC0-Last of Embibatinib under fed versus fasted conditions.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  2. AUC0-Inf of Embibatinib in Plasma Under Fed Versus Fasted Conditions

    Blood samples will be collected to determine the AUC0-inf of Embibatinib under fed versus fasted conditions.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  3. Cmax of Embibatinib in Plasma Under Fed Versus Fasted Conditions

    Blood samples will be collected to determine the Cmax of Embibatinib under fed versus fasted conditions.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  4. Tmax of Embibatinib in Plasma Under Fed Versus Fasted Conditions

    Blood samples will be collected to determine the Tmax of Embibatinib under fed versus fasted conditions.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  5. AUC0-last of Embibatinib Formulations in Plasma

    Blood samples will be collected to determine the AUC0-Last of Embibatinib formulations.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  6. AUC0-Inf of Embibatinib Formulations in Plasma

    Blood samples will be collected to determine the AUC0-Inf of Embibatinib formulations.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  7. Cmax of Embibatinib Formulations in Plasma

    Blood samples will be collected to determine the Cmax of Embibatinib formulations.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  8. AUC0-last of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent

    Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without an acid-reducing agent.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  9. AUC0-Inf of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent

    Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without an acid-reducing agent.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  10. Cmax of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent

    Blood samples will be collected to determine the Cmax of Embibatinib administered with or without an acid-reducing agent.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  11. AUC0-last of Midazolam in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Midazolam administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  12. AUC0-Inf of Midazolam in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Midazolam administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  13. Cmax of Midazolam in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Midazolam administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  14. AUC0-last of Montelukast in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Montelukast administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  15. AUC0-Inf of Montelukast in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Montelukast administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  16. Cmax of Montelukast in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Montelukast administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  17. AUC0-last of Omeprazole in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Omeprazole administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  18. AUC0-Inf of Omeprazole in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Omeprazole administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  19. Cmax of Omeprazole in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Omeprazole administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  20. AUC0-last of Digoxin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Digoxin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  21. AUC0-Inf of Digoxin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Digoxin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  22. Cmax of Digoxin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Digoxin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  23. AUC0-last of Pravastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Pravastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  24. AUC0-Inf of Pravastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Pravastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  25. Cmax of Pravastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Pravastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  26. AUC0-last of Warfarin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Warfarin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  27. AUC0-Inf of Warfarin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Warfarin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  28. Cmax of Warfarin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Warfarin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  29. AUC0-last of Rosuvastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-Last of Rosuvastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  30. AUC0-Inf of Rosuvastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the AUC0-inf of Rosuvastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  31. Cmax of Rosuvastatin in Plasma Administered With or Without Embibatinib

    Blood samples will be collected to determine the Cmax of Rosuvastatin administered with or without Embibatinib.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  32. AUC0-last of Embibatinib in Plasma Administered With or Without Itraconazole

    Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without itraconazole.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  33. AUC0-Inf of Embibatinib in Plasma Administered With or Without Itraconazole

    Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without itraconazole.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  34. Cmax of Embibatinib in Plasma Administered With or Without Itraconazole

    Blood samples will be collected to determine the Cmax of Embibatinib administered with or without itraconazole.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  35. AUC0-last of Embibatinib in Plasma Administered With or Without Bosentan

    Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without Bosentan.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  36. AUC0-Inf of Embibatinib in Plasma Administered With or Without Bosentan

    Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without Bosentan.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  37. Cmax of Embibatinib in Plasma Administered With or Without Bosentan

    Blood samples will be collected to determine the Cmax of Embibatinib administered with or without Bosentan.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  38. AUC0-last of Embibatinib in Plasma Administered With or Without Quinidine

    Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without Quinidine.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  39. AUC0-Inf of Embibatinib in Plasma Administered With or Without Quinidine

    Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without Quinidine.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

  40. Cmax of Embibatinib in Plasma Administered With or Without Quinidine

    Blood samples will be collected to determine the Cmax of Embibatinib administered with or without Quinidine.

    Time frame: Pre-dose and at designated time points up to 96 hours post dose

07

Study locations

1 site
  • ICON
    Millcreek, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jun 2026, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 24, 2026
StartActual
Dec 21, 2023
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHas any known history of bleeding, or prothrombin time (TERN-701Embibatinib + Probe Substrate Cocktail-2 arm only)
Oct 22, 2026
Interventions
Changed TERN-701→Embibatinib. Arm changed Cohort 1: Single Ascending Dose (SAD) Escalation of TERN-701 Dose Level 1→Cohort 1: Single Ascending Dose (SAD) Escalation of Embibatinib Dose Level 1; Cohort 2: SAD Escalation of TERN-701 Dose Level 2→Cohort 2: SAD Escalation of Embibatinib Dose Level 2; Cohort 3: SAD Escalation of TERN-701 Dose Level 3 and Food Effect→Cohort 3: SAD Escalation of Embibatinib Dose Level 3 and Food Effect; Cohort 4: SAD Escalation of TERN-701 Dose Level 4→Cohort 4: SAD Escalation of Embibatinib Dose Level 4; Cohort 5: SAD Escalation of TERN-701 Dose Level 5→Cohort 5: SAD Escalation of Embibatinib Dose Level 5; Cohort 6: SAD Escalation of TERN-701 Dose Level 7→Cohort 6: SAD Escalation of Embibatinib Dose Level 7; Cohort 7: TERN-701 Formulations with Rabeprazole 20 mg→Cohort 7: Embibatinib Formulations with Rabeprazole 20 mg; Cohort 8: TERN-701 + Probe Substrate Cocktail-1→Cohort 8: Embibatinib + Probe Substrate Cocktail-1; Cohort 9: TERN-701 Dose Level 5 + Rabeprazole 20 mg→Cohort 9: Embibatinib Dose Level 5 + Rabeprazole 20 mg; Cohort 10: SAD Escalation of TERN-701 Dose Level 8→Cohort 10: SAD Escalation of Embibatinib Dose Level 8; Cohort 11: SAD Escalation of TERN-701 Dose Level 9→Cohort 11: SAD Escalation of Embibatinib Dose Level 9; Cohort 12: TERN-701 Dose Level 3 + Itraconazole 200 mg→Cohort 12: Embibatinib Dose Level 3 + Itraconazole 200 mg; Cohort 13: Multiple Ascending Dose (MAD) Escalation of TERN-701 Dose Level 4→Cohort 13: Multiple Ascending Dose (MAD) Escalation of Embibatinib Dose Level 4; Cohort 14: TERN-701 Dose Level 5 + Probe Substrate Cocktail-2→Cohort 14: Embibatinib Dose Level 5 + Probe Substrate Cocktail-2; Cohort 15: TERN-701 Dose Level 8 + Probe Substrate Cocktail-2→Cohort 15: Embibatinib Dose Level 8 + Probe Substrate Cocktail-2; Cohort 16: Food Effect on TERN-701 Dose Level 8 Formulations with Rabeprazole 20 mg→Cohort 16: Food Effect on Embibatinib Dose Level 8 Formulations with Rabeprazole 20 mg; Cohort 17: Food Effect on TERN-701 Dose Level 8 Selected Formulation with Rabeprazole 20 mg→Cohort 17: Food Effect on Embibatinib Dose Level 8 Selected Formulation with Rabeprazole 20 mg; Cohort 18: TERN-701 Dose Level 8 + Bosentan 125 mg→Cohort 18: Embibatinib Dose Level 8 + Bosentan 125 mg; Cohort 19: TERN-701 Dose Level 6 + Quinidine 300 mg→Cohort 19: Embibatinib Dose Level 6 + Quinidine 300 mg
Oct 22, 2026
Primary outcomes
6 edited
What changed in the outcomes
  • EditedArea Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedArea Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedArea Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose
  • EditedMaximum Observed Concentration of Drug (Cmax) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedApparent Terminal Elimination Half-Life (t1/2) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedTime of Maximum Observed Concentration of Drug (Tmax) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
Oct 22, 2026
Secondary outcomes
30 edited, 10 more
What changed in the outcomes
  • EditedAUC0-last of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedTmax of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedCmax of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-last of Rosuvastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • EditedAUC0-Inf of Rosuvastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
  • …and 10 more, on the record history on ClinicalTrials.gov ↗
Oct 22, 2026
Title
A Clinical Trial to Evaluate MK-4208/TERN-701Embibatinib in Healthy Adult Participants (MK-4208-001/TERN701Embibatinib-1014)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHas any known history of bleeding, or prothrombin time (TERN-701Embibatinib + Probe Substrate Cocktail-2 arm only)
    Primary outcomes 6 edited
    What changed in the outcomes
    • EditedArea Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedArea Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedArea Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose
    • EditedMaximum Observed Concentration of Drug (Cmax) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedApparent Terminal Elimination Half-Life (t1/2) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedTime of Maximum Observed Concentration of Drug (Tmax) of TERN-701Embibatinib in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    Secondary outcomes 30 edited, 10 more
    What changed in the outcomes
    • EditedAUC0-last of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedTmax of TERN-701Embibatinib in Plasma Under Fed Versus Fasted ConditionsTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of TERN-701Embibatinib Formulations in PlasmaTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of TERN-701Embibatinib in Plasma Administered With or Without an Acid-Reducing AgentTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Midazolam in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Montelukast in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Omeprazole in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Digoxin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Pravastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedCmax of Warfarin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-last of Rosuvastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • EditedAUC0-Inf of Rosuvastatin in Plasma Administered With or Without TERN-701EmbibatinibTime frame: Pre-dose and at designated time points up to 96 hours post dose
    • …and 10 more, on the record history on ClinicalTrials.gov ↗
    Interventions Changed TERN-701→Embibatinib. Arm changed Cohort 1: Single Ascending Dose (SAD) Escalation of TERN-701 Dose Level 1→Cohort 1: Single Ascending Dose (SAD) Escalation of Embibatinib Dose Level 1; Cohort 2: SAD Escalation of TERN-701 Dose Level 2→Cohort 2: SAD Escalation of Embibatinib Dose Level 2; Cohort 3: SAD Escalation of TERN-701 Dose Level 3 and Food Effect→Cohort 3: SAD Escalation of Embibatinib Dose Level 3 and Food Effect; Cohort 4: SAD Escalation of TERN-701 Dose Level 4→Cohort 4: SAD Escalation of Embibatinib Dose Level 4; Cohort 5: SAD Escalation of TERN-701 Dose Level 5→Cohort 5: SAD Escalation of Embibatinib Dose Level 5; Cohort 6: SAD Escalation of TERN-701 Dose Level 7→Cohort 6: SAD Escalation of Embibatinib Dose Level 7; Cohort 7: TERN-701 Formulations with Rabeprazole 20 mg→Cohort 7: Embibatinib Formulations with Rabeprazole 20 mg; Cohort 8: TERN-701 + Probe Substrate Cocktail-1→Cohort 8: Embibatinib + Probe Substrate Cocktail-1; Cohort 9: TERN-701 Dose Level 5 + Rabeprazole 20 mg→Cohort 9: Embibatinib Dose Level 5 + Rabeprazole 20 mg; Cohort 10: SAD Escalation of TERN-701 Dose Level 8→Cohort 10: SAD Escalation of Embibatinib Dose Level 8; Cohort 11: SAD Escalation of TERN-701 Dose Level 9→Cohort 11: SAD Escalation of Embibatinib Dose Level 9; Cohort 12: TERN-701 Dose Level 3 + Itraconazole 200 mg→Cohort 12: Embibatinib Dose Level 3 + Itraconazole 200 mg; Cohort 13: Multiple Ascending Dose (MAD) Escalation of TERN-701 Dose Level 4→Cohort 13: Multiple Ascending Dose (MAD) Escalation of Embibatinib Dose Level 4; Cohort 14: TERN-701 Dose Level 5 + Probe Substrate Cocktail-2→Cohort 14: Embibatinib Dose Level 5 + Probe Substrate Cocktail-2; Cohort 15: TERN-701 Dose Level 8 + Probe Substrate Cocktail-2→Cohort 15: Embibatinib Dose Level 8 + Probe Substrate Cocktail-2; Cohort 16: Food Effect on TERN-701 Dose Level 8 Formulations with Rabeprazole 20 mg→Cohort 16: Food Effect on Embibatinib Dose Level 8 Formulations with Rabeprazole 20 mg; Cohort 17: Food Effect on TERN-701 Dose Level 8 Selected Formulation with Rabeprazole 20 mg→Cohort 17: Food Effect on Embibatinib Dose Level 8 Selected Formulation with Rabeprazole 20 mg; Cohort 18: TERN-701 Dose Level 8 + Bosentan 125 mg→Cohort 18: Embibatinib Dose Level 8 + Bosentan 125 mg; Cohort 19: TERN-701 Dose Level 6 + Quinidine 300 mg→Cohort 19: Embibatinib Dose Level 6 + Quinidine 300 mg
    Title A Clinical Trial to Evaluate MK-4208/TERN-701Embibatinib in Healthy Adult Participants (MK-4208-001/TERN701Embibatinib-1014)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07838987
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Dec 21, 2023
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Oct 22, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Embibatinib

Start the discussion